ZA916555B - Method of treating inflammatory bowel disease - Google Patents

Method of treating inflammatory bowel disease

Info

Publication number
ZA916555B
ZA916555B ZA916555A ZA916555A ZA916555B ZA 916555 B ZA916555 B ZA 916555B ZA 916555 A ZA916555 A ZA 916555A ZA 916555 A ZA916555 A ZA 916555A ZA 916555 B ZA916555 B ZA 916555B
Authority
ZA
South Africa
Prior art keywords
inflammatory bowel
bowel disease
treating inflammatory
treating
disease
Prior art date
Application number
ZA916555A
Other languages
English (en)
Inventor
Jill Ann Panetta
Ann Panetta Jill
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA916555B publication Critical patent/ZA916555B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA916555A 1990-08-27 1991-08-19 Method of treating inflammatory bowel disease ZA916555B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57228690A 1990-08-27 1990-08-27

Publications (1)

Publication Number Publication Date
ZA916555B true ZA916555B (en) 1993-04-28

Family

ID=24287150

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA916555A ZA916555B (en) 1990-08-27 1991-08-19 Method of treating inflammatory bowel disease

Country Status (10)

Country Link
US (1) US5552439A (fr)
EP (1) EP0474403B1 (fr)
JP (1) JPH04230622A (fr)
KR (1) KR920003968A (fr)
AU (1) AU642762B2 (fr)
CA (1) CA2049481A1 (fr)
DE (1) DE69109583T2 (fr)
ES (1) ES2071930T3 (fr)
HU (1) HUT61661A (fr)
ZA (1) ZA916555B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4204405A1 (de) * 1991-08-02 1993-02-04 Boehringer Mannheim Gmbh Verwendung von di-tert.-butylhydroxyphenyl-derivaten zur therapie von entzuendlichen erkrankungen des magen-darm-traktes
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US5633283A (en) * 1995-01-23 1997-05-27 Eli Lilly And Company Method for treating multiple sclerosis
JP3299100B2 (ja) * 1995-12-05 2002-07-08 株式会社資生堂 フェニレンジアミン誘導体及びラジカルスカベンジャー、脳梗塞抑制剤、脳浮腫抑制剤
US6083989A (en) 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
EP1079820A1 (fr) * 1998-05-19 2001-03-07 Centaur Pharmaceuticals, Inc. Medicament a base de benzamide, destine au traitement des affections inflammatoires de l'intestin
WO2001035950A2 (fr) * 1999-11-18 2001-05-25 Centaur Pharmaceuticals, Inc. Agent therapeutique a base d'amide et procedes de traitement des affections intestinales inflammatoires
US6989377B2 (en) 1999-12-21 2006-01-24 Wisconsin Alumni Research Foundation Treating vitamin D responsive diseases
US6358939B1 (en) 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
US6689788B1 (en) 2000-08-25 2004-02-10 University Of Florida Method and composition for treatment of inflammatory bowel disease
US20030118329A1 (en) * 2001-12-21 2003-06-26 Pere Obrador Video indexing using high resolution still images
IL152127A0 (en) * 2002-10-06 2003-05-29 Bio Balance Corp Probiotic compositions for the treatment of inflammatory bowel disease
US7417037B2 (en) * 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
ME01541B (me) 2005-04-13 2014-04-20 Astex Therapeutics Ltd DERIVATI HIDROKSIBENZAMIDA l NJIHOVA PRIMJENA KAO INHIBITORA HSP90
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
WO2008044029A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
JP5410285B2 (ja) 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2073807A1 (fr) 2006-10-12 2009-07-01 Astex Therapeutics Limited Combinaisons pharmaceutiques
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
US7923014B2 (en) * 2007-02-12 2011-04-12 The Board Of Regents Of The University Of Texas System Expression and purification of HIP/PAP and uses therefor
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
WO2010042933A2 (fr) 2008-10-10 2010-04-15 Northwestern University Inhibition et traitement des métastases du cancer de la prostate
WO2016073897A1 (fr) 2014-11-06 2016-05-12 Northwestern University Inhibition de la motilité de cellules cancéreuses
US10449198B2 (en) 2016-07-01 2019-10-22 The University Of Liverpool Method for treating pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043774A (en) * 1955-09-23 1962-07-10 Ethyl Corp Organic compositions
NL126252C (fr) * 1961-07-28 1900-01-01 United States Rubber Co
US3305483A (en) * 1964-12-03 1967-02-21 Ethyl Corp Stabilized organic compositions
US3809761A (en) * 1970-03-12 1974-05-07 Ethyl Corp Method for reducing plasma lipid levels
US3792170A (en) * 1972-03-14 1974-02-12 Merck & Co Inc Novel alkylsulfinyl derivatives for pain,fever and inflammation
DE2240609A1 (de) * 1972-08-18 1974-02-28 Hoechst Ag Stoffwechselwirksame derivate der 4-hydroxy-3,5-di-alkylphenyl-propionsaeure
US4073942A (en) * 1972-10-23 1978-02-14 Boehringer Ingelheim Gmbh Halo-substituted hydroxybenzyl-amines as secretolytic agents
GB1405767A (en) * 1972-12-14 1975-09-10 Ethyl Corp Method formulation and pharmaceutical composition for reducing plasma lipid levels
US3994828A (en) * 1973-06-07 1976-11-30 Dynapol Corporation Nonabsorbable antioxidant
US4116930A (en) * 1975-11-03 1978-09-26 Ciba-Geigy Corporation Pyromellitic dimiides of 3,5-dialkyl-4-hydroxyphenylsubstituted amines
US4128664A (en) * 1977-05-16 1978-12-05 Riker Laboratories, Inc. Substituted benzamides as anti-inflammatory agents
US4324717A (en) * 1980-06-23 1982-04-13 The B. F. Goodrich Company Norbornene polymers stabilized with hindered aromatic alcohols
US4562201A (en) * 1982-07-26 1985-12-31 American Hospital Supply Corporation Aminomethyl benzanilides
JPS6061523A (ja) * 1983-09-16 1985-04-09 Shionogi & Co Ltd 経口用ドブタミン製剤
US4532356A (en) * 1983-11-16 1985-07-30 Ethyl Corporation Chemical process
GB8501646D0 (en) * 1985-01-23 1985-02-27 Nipa Lab Ltd Control of micro-organisms
US4959503A (en) * 1986-04-11 1990-09-25 Warner-Lambert Company Diarylalkanoids having activity as lipoxygenase inhibitors
IT1204416B (it) * 1986-06-27 1989-03-01 Midy Spa Medicamenti a base di analoghi di feniletanolammine per il trattamento di disturbi gastro-intestinali ed uterini
US4708966A (en) * 1986-06-27 1987-11-24 The Procter & Gamble Company Novel anti-inflammatory agents, pharmaceutical compositions and methods for reducing inflammation
DE3702755A1 (de) * 1987-01-30 1988-08-11 Hoechst Ag 3,5-di-tert.-butyl-4-hydroxybenzoesaeureamid, verschiedene von dessen derivaten, verfahren zur herstellung dieser verbindungen, die sie enthaltenden arzneimittel und ihre verwendung
US4948813A (en) * 1987-11-30 1990-08-14 E. I. Du Pont De Nemours And Company Benzylketone phospholipase A2 inhibitors
DE3903989A1 (de) * 1989-02-10 1990-09-20 Basf Ag Diphenylheteroalkylderivate, ihre herstellung und daraus hergestellte arzneimittel und kosmetika
EP0385043A1 (fr) * 1989-02-28 1990-09-05 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes) Dérivés de pipérazinessubstituées en 4

Also Published As

Publication number Publication date
HU912792D0 (en) 1992-01-28
AU8278291A (en) 1992-03-05
CA2049481A1 (fr) 1992-02-28
EP0474403A1 (fr) 1992-03-11
DE69109583T2 (de) 1995-10-12
KR920003968A (ko) 1992-03-27
JPH04230622A (ja) 1992-08-19
ES2071930T3 (es) 1995-07-01
AU642762B2 (en) 1993-10-28
DE69109583D1 (de) 1995-06-14
US5552439A (en) 1996-09-03
HUT61661A (en) 1993-03-01
EP0474403B1 (fr) 1995-05-10

Similar Documents

Publication Publication Date Title
ZA916555B (en) Method of treating inflammatory bowel disease
IL117417A0 (en) Method of treating cardiac inflammatory disease
PH17040A (en) Method and compounds for treating inflammatory bowel disease
GB9027968D0 (en) Method of treatment
PL290856A1 (en) Method of obtaining Ÿ-lactames
ZA914435B (en) Treatment of disease
EP0469443A3 (en) Method of treating waste
PL288627A1 (en) Method of obtaining pentafluorodichloropropanes
ZA915682B (en) Method of treatment of allergic conjunctivitis
PL283907A1 (en) Method of obtaining oligoestrols
AU9055091A (en) Treatment for inflammatory bowel disease
PL292308A1 (en) Method of obtaining tioxane
PL287126A1 (en) Method of obtaining pululane
GB9111703D0 (en) Method of transsilylation
PL285570A1 (en) Method of obtaining n-2-minoethyl-3-aminopropyltrimethoxysilane
GB9014959D0 (en) Method of treatment
PL286564A1 (en) Method of treatment of extragrade pantaerythrite
GB9001031D0 (en) Method of treatment
GB9026564D0 (en) Method of treatment
GB9016831D0 (en) Method of treatment
GB9001028D0 (en) Method of treatment
GB9001029D0 (en) Method of treatment
GB9023600D0 (en) Method of treating demyelinating disease
GB9023607D0 (en) Method of treating demyelinating disease
RU1833722C (ru) Cпocoб лeчehия cиhдaktилии